Product Center
Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine marketing application has been accepted by the National Medical Products Administration!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21
- Views:
(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accep
Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine marketing application has been accepted by the National Medical Products Administration!
(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accep
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21 16:16
- Views:
Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by NMPA.
Source: CDE website
The Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine is a component vaccine containing a new antigen form, characterized by high purity, low vaccination side effects, and good safety. In 2016, the company applied for clinical trials of the quadrivalent influenza virus subunit vaccine using its own patented technology. In 2017, the company obtained clinical approval for two biological product class I new drugs in adult and child dosage forms. From 2018 to 2021, the phase I/III clinical trial was successfully completed, and all relevant trial results reached clinical endpoints, showing significant positive results in immunogenicity and safety. The clinical results show that the full dose unadjuvant (0.5ml) quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted for the company's listing application, is a safe and effective influenza vaccine that can provide broader and sufficient protection against seasonal influenza viruses. This vaccine is expected to serve as an important member of the influenza prevention strategy and contribute China's efforts to the global prevention and control of influenza virus outbreaks and infections.
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
